Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Change in Cash: 2009-2025

Historic Change in Cash for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $2.8 million.

  • Lifecore Biomedical's Change in Cash fell 47.15% to $2.8 million in Q2 2025 from the same period last year, while for May 2025 it was -$197,000, marking a year-over-year increase of 98.15%. This contributed to the annual value of -$197,000 for FY2025, which is 98.15% up from last year.
  • As of Q2 2025, Lifecore Biomedical's Change in Cash stood at $2.8 million, which was up 170.53% from -$4.0 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Change in Cash registered a high of $16.1 million during Q2 2023, and its lowest value of -$10.4 million during Q3 2023.
  • Over the past 3 years, Lifecore Biomedical's median Change in Cash value was -$1.5 million (recorded in 2024), while the average stood at $143,500.
  • As far as peak fluctuations go, Lifecore Biomedical's Change in Cash skyrocketed by 7,749.76% in 2023, and later tumbled by 2,628.38% in 2025.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Change in Cash stood at -$356,000 in 2021, then surged by 832.58% to $2.6 million in 2022, then plummeted by 307.86% to -$5.4 million in 2023, then surged by 172.59% to $3.9 million in 2024, then plummeted by 47.15% to $2.8 million in 2025.
  • Its Change in Cash was $2.8 million in Q2 2025, compared to -$4.0 million in Q1 2025 and $3.9 million in Q4 2024.